Combined miRNA transcriptome and proteome analysis of extracellular vesicles in urine and blood from the Pompe mouse model.


Journal

Annals of medicine
ISSN: 1365-2060
Titre abrégé: Ann Med
Pays: England
ID NLM: 8906388

Informations de publication

Date de publication:
Dec 2024
Historique:
medline: 24 10 2024
pubmed: 24 10 2024
entrez: 24 10 2024
Statut: ppublish

Résumé

Acid α-glucosidase (GAA) is a lysosomal enzyme that hydrolyzes glycogen to glucose. Deficiency of GAA causes Pompe disease (PD), also known as glycogen storage disease type II. The resulting glycogen accumulation causes a spectrum of disease severity ranging from infantile-onset PD to adult-onset PD. Additional non-invasive biomarkers of disease severity are needed to monitor response to therapeutic interventions. We measured protein and miRNA abundance in exosomes from serum and urine from the PD mouse model (B6;129-GaaTm1Rabn/J), wild-type mice, and PD mice treated with a candidate gene therapy. There were significant differences in the abundance of 113 miRNA in serum exosomes from Pompe versus healthy mice. Levels of miR-206, miR-133, miR-1a, miR-486, and other important regulators of muscle development and maintenance were altered in the Pompe samples. The serum and urine exosome proteomes of healthy and Pompe mice also differed broadly. Several of the dysregulated proteins are encoded by genes with potential target sites for affected miRNA. Exosomes derived from urine or serum are a potential source of biomarkers for Pompe Disease. Further study of the differences in the miRNA transcriptome and proteome content of exosomes may yield new insights into disease mechanisms.

Identifiants

pubmed: 39445404
doi: 10.1080/07853890.2024.2402503
doi:

Substances chimiques

MicroRNAs 0
Proteome 0
Biomarkers 0
alpha-Glucosidases EC 3.2.1.20

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2402503

Auteurs

David Merberg (D)

Takeda Pharmaceutical Company Limited, Rare Disease Drug Discovery Unit, Cambridge, MA, USA.

Rodney Moreland (R)

Takeda Pharmaceutical Company Limited, Rare Disease Drug Discovery Unit, Cambridge, MA, USA.

Zhenqiang Su (Z)

Takeda Pharmaceutical Company Limited, Preclinical and Translational Sciences, Cambridge, MA, USA.

Bin Li (B)

Takeda Pharmaceutical Company Limited, Preclinical and Translational Sciences, Cambridge, MA, USA.

Bob Crooker (B)

Takeda Pharmaceutical Company Limited, Rare Disease Drug Discovery Unit, Cambridge, MA, USA.

Kathleen Palmieri (K)

Takeda Pharmaceutical Company Limited, Rare Disease Drug Discovery Unit, Cambridge, MA, USA.

Simon W Moore (SW)

Takeda Pharmaceutical Company Limited, Rare Disease Drug Discovery Unit, Cambridge, MA, USA.

Andrew Melber (A)

Takeda Pharmaceutical Company Limited, Rare Disease Drug Discovery Unit, Cambridge, MA, USA.

Ruby Boyanapalli (R)

Takeda Pharmaceutical Company Limited, Rare Disease Drug Discovery Unit, Cambridge, MA, USA.

Galen Carey (G)

Takeda Pharmaceutical Company Limited, Rare Disease Drug Discovery Unit, Cambridge, MA, USA.

Mahindra Makhija (M)

Takeda International - UK, London, England.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH